由于疗效不足, 暂停了对克拉扎齐祖马布治疗慢性排斥的第三期试验. Phase 3 trial of clazakizumab for chronic kidney rejection halted due to insufficient efficacy.

由于初步分析显示该药物无法达到疗效目标,因此停止了评估clazakizumab作为治疗慢性活性抗体媒介排斥的3期试验. A phase 3 trial evaluating clazakizumab as a treatment for chronic active antibody-mediated rejection in kidney transplant patients has been halted after interim analysis indicated it would not meet efficacy goals. 尽管之前的 2 期结果很有希望，但该试验发现与安慰剂相比，肾功能没有显着差异。 Though previous phase 2 results were promising, the trial found no significant difference in kidney function compared to placebo. 预计最后结果将在2024年ASN肾脏周上公布,对未来的肾移植疗法有影响。 The final results are expected to be presented at ASN Kidney Week 2024, with implications for future kidney transplant therapies.